ConductScience.org, home

Paper41587134

MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy.

Zhou AW and 24 others. Ophthalmologica, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy. Papers, record 41587134. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41587134

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy.
PubMed
Journal
Ophthalmologica
PubMed
Year
2026
PubMed
Publication types
Journal Article, Multicenter Study, Randomized Controlled Trial, Clinical Trial, Phase II
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-20
PubMed

Authors25

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhou AWAvery W
2Sahraravand RARyan A
3Baumann LMLiisa M
4Teagle GMGail Megan
5Brown JJeremiah
6Pieramici DDante
7Holy SESarah E
8Borne MJMichael J
9Wong RWRobert W
10Cunningham MAMatthew A
11Pearce WAWilliam A
12Rahman EZEffie Z
13Chang MMargaret
14Bhavsar ARAbdhish R
15Brown DMDavid M
16Alfaro DVDaniel Virgil
17Fan KCKenneth C
18Cehofski LJLasse Jørgensen
19Ip MMichael
20Sadda SRSrinivas R

Source PubMed

See all 25 authorsDownload CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Diabetic RetinopathyMajor topic
Fluorescein AngiographyMajor topic
Visual AcuityMajor topic
RetinaMajor topic
Humans
Prospective Studies
Intravitreal Injections
Tomography, Optical Coherence
Fundus Oculi
Female
Follow-Up Studies
Treatment Outcome
Male
Antibodies, Bispecific

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT05681884Safety and Efficacy of Faricimab in Patients With NPDRDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References42

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115215160Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.Am J Pathol2004https://conductscience.org/library/papers/15215160PubMed
231383483Widefield OCT-Angiography and Fluorescein Angiography Assessments of Nonperfusion in Diabetic Retinopathy and Edema Treated with Anti-Vascular Endothelial Growth Factor.Ophthalmology2019https://conductscience.org/library/papers/31383483PubMed
326841250Contemporary retinal imaging techniques in diabetic retinopathy: a review.Clin Exp Ophthalmol2016https://conductscience.org/library/papers/26841250PubMed
432866468A critical review: Psychophysical assessments of diabetic retinopathy.Surv Ophthalmol2021https://conductscience.org/library/papers/32866468PubMed
526469537DETECTION OF MICROVASCULAR CHANGES IN EYES OF PATIENTS WITH DIABETES BUT NOT CLINICAL DIABETIC RETINOPATHY USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.Retina2015https://conductscience.org/library/papers/26469537PubMed
627120074Evaluating the performance of the quick CSF method in detecting contrast sensitivity function changes.J Vis2016https://conductscience.org/library/papers/27120074PubMed
729752001Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.Ophthalmology2018https://conductscience.org/library/papers/29752001PubMed
826350546Diabetic Retinopathy Severity and Peripheral Lesions Are Associated with Nonperfusion on Ultrawide Field Angiography.Ophthalmology2015https://conductscience.org/library/papers/26350546PubMed
927472275Linking Retinal Microvasculature Features With Severity of Diabetic Retinopathy Using Optical Coherence Tomography Angiography.Invest Ophthalmol Vis Sci2016https://conductscience.org/library/papers/27472275PubMed
1029545417Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections.Br J Ophthalmol2018https://conductscience.org/library/papers/29545417PubMed
1122402896Vision, retinal thickness, and foveal avascular zone size after intravitreal bevacizumab for diabetic macular edema.Adv Ther2012https://conductscience.org/library/papers/22402896PubMed
1236749332Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.JAMA2023https://conductscience.org/library/papers/36749332PubMed
1323355773Changes in the foveal microstructure after intravitreal bevacizumab application in patients with retinal vascular disease.Clin Ophthalmol2013https://conductscience.org/library/papers/23355773PubMed
1438881606Visual Function Measurements in Eyes With Diabetic Retinopathy: An Expert Opinion on Available Measures.Ophthalmol Sci2024https://conductscience.org/library/papers/38881606PubMed
1527847598A review of optical coherence tomography angiography (OCTA).Int J Retina Vitreous2015https://conductscience.org/library/papers/27847598PubMed
1635257962Final Outcomes from the Randomized RECOVERY Trial of Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy.Ophthalmol Retina2022https://conductscience.org/library/papers/35257962PubMed
1735980610Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time.JAMA Ophthalmol2022https://conductscience.org/library/papers/35980610PubMed
1823706926Contrast sensitivity basics and a critique of currently available tests.J Cataract Refract Surg2013https://conductscience.org/library/papers/23706926PubMed
1917166891Clinical assessment of two new contrast sensitivity charts.Br J Ophthalmol2007https://conductscience.org/library/papers/17166891PubMed
2035017700Retinal non-perfusion in diabetic retinopathy.Eye (Lond)2022https://conductscience.org/library/papers/35017700PubMed

See all 42 referencesDownload CSV of references

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
FARICIMABCHEMBL4297750Derived from the trial1https://conductscience.org/library/drugs/CHEMBL4297750

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Cited by
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41587134

GET https://conductscience.org/api/papers/v1/41587134/authors?page=2